Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity plan transaction rather than general financial performance.
Material Changes
The filing details an increase in the notional interest in Ordinary Shares for a connected person, Mrs. K Thomson (connected to Director Mr. P C Thomson). This change reflects a reconciliation of notional dividends following a change in Plan administration to ensure the originally intended number of dividends accrues over the vesting period. The notional dividends were re-invested on July 8, 2013, at an average price of 1413.90 pence per Ordinary Share, resulting in an increase of 33,617 Ordinary Shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c). The payout of accrued notional dividends is contingent upon the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant measurement period.
Investor Verification Points
- Verify the vesting conditions and measurement period for the 2011 Performance Share Plan award held by Mr. P C Thomson.
- Confirm the impact of the Plan administration change on other participants' notional dividend accruals.
- Review the total shareholding of connected persons to assess potential insider trading implications or concentration risks.